Velcade's Muscle Pain: Understanding The Connection

Velcade (bortezomib) is a prescription drug used to treat multiple myeloma and mantle cell lymphoma. It is administered via injection and works by blocking cancer cells from breaking down proteins, causing cell death. While Velcade is effective in cancer treatment, it can cause various side effects, including muscle pain or muscle cramps. This myalgia is often associated with peripheral neuropathy, which refers to nerve damage typically affecting the arms, hands, legs, or feet. Patients may experience pain, numbness, or weakness in these areas due to nerve problems. Other side effects of Velcade include fatigue, digestive issues, rash, low blood pressure, and heart and lung problems. It is important to monitor for these side effects and consult a doctor if they occur.

Explore related products

My Bout with Multiple Myeloma

$6.99 $18.04

Understanding Velcade (bortezomib) for Injection

$0.99

Peripheral neuropathy

Velcade (bortezomib) is a prescription drug used to treat multiple myeloma and mantle cell lymphoma. It can cause peripheral neuropathy, which refers to nerve damage that typically affects the arms, hands, legs, or feet. Peripheral neuropathy was a more common side effect in clinical trials of the drug.

Symptoms of peripheral neuropathy include pain, numbness, a burning feeling, tingling, squeezing, pinching, aching, and weakness. These symptoms usually appear within the first few cycles of treatment or when the cumulative dose reaches about 26 mg/m2. On examination, distal sensory loss is exhibited, along with possible changes in proprioception and diminished or absent deep tendon reflexes. Motor skills may also be affected, with distal weakness observed in the lower extremities.

The incidence of peripheral neuropathy was found to be significantly lower with subcutaneous administration (38%) compared to intravenous administration (53%). The subcutaneous route reduces the incidence of high peak medication levels, resulting in fewer direct damaging effects on the dorsal root ganglion.

In a study of 256 patients with relapsed and/or refractory myeloma treated with bortezomib, 35% reported treatment-emergent neuropathy. Of these, 22% experienced Grade 1 or 2 neuropathy, 13% experienced Grade 3 neuropathy, and 0.4% experienced Grade 4 neuropathy. The incidence of Grade ≥ 3 neuropathy was higher among patients with baseline neuropathy (14%) compared to those without (4%).

Resolution or improvement of peripheral neuropathy was observed in 71% of patients with neuropathy ≥ Grade 3 and/or requiring discontinuation. In most cases, peripheral neuropathy resolved within 3 months after completing or discontinuing bortezomib treatment. However, in less common cases, it could take a couple of years, and in some instances, it may be a long-term sequela from treatment.

Heart problems

Velcade (bortezomib) is a prescription drug used to treat multiple myeloma and mantle cell lymphoma. It is administered via injection.

Velcade can cause new or worsening heart disease, including heart failure and cardiomyopathy (a weakened heart muscle). Heart-related side effects were common in clinical trials of the drug. If you have a history of heart problems, be sure to talk to your doctor before starting Velcade.

Velcade may also cause cardiac amyloidosis, a condition that causes a buildup of protein in the heart muscle. It can also cause or worsen heart rhythm problems.

Symptoms of heart-related problems with Velcade can include chest tightness, difficulty breathing, and swelling in the arms or legs. If you experience any of these symptoms, tell your doctor as soon as possible. They may want to check your heart. If your symptoms feel severe or life-threatening, call an emergency number right away.

In addition, Velcade can cause low blood pressure. If you have a history of fainting, dehydration, or are taking certain medications, you may be at an increased risk of low blood pressure while taking Velcade. Discuss your medical history and current medications with your doctor before starting Velcade.

Injection site reactions

Velcade (bortezomib) is available in an injectable form that is given by a healthcare provider. It is very common to experience injection site reactions with this medicine. With these reactions, you have inflammation in the tissue where the drug was injected. This can cause redness, swelling, and pain in the area. It’s not known for sure how many people taking Velcade have had an injection site reaction. However, most injection site reactions are mild and typically last for a few hours to a few days.

If you have severe swelling, pain, or redness at your injection site that lasts more than a few days, call your doctor. They can recommend ways to help relieve your discomfort. Injection site reactions are additional side effects that can happen with bortezomib.

It is important to note that bortezomib will be given to you by your healthcare provider; it is not a medicine that you will take at home. Bortezomib is usually given by a healthcare provider in a hospital or clinic.

Liver damage

Velcade (bortezomib) is broken down by the liver. If you have liver problems, your body might struggle to eliminate this medication, leading to higher levels of Velcade in your system and an increased risk of side effects. Therefore, it is crucial to inform your healthcare provider if you have any liver issues before starting treatment with Velcade. Depending on the severity of your liver problems, your doctor may recommend initiating Velcade at a lower dosage, and you will likely require closer monitoring.

In addition to liver damage, Velcade has been associated with other serious side effects, including severe skin reactions, lung damage, brain swelling, infections such as pneumonia, clotting disorders, tumour lysis syndrome, kidney disease, and heart disease. While serious side effects are uncommon, they can occur, and it is imperative to be vigilant and seek medical advice if any symptoms arise.

To ensure the safe use of Velcade, regular medical progress checks are crucial. Blood and urine tests may be necessary to monitor for any unwanted effects, including liver damage. Furthermore, female patients should use effective contraception during treatment and for at least seven months after the last dose, as Velcade can cause harm to an unborn baby and may lead to birth defects.

In summary, liver damage is a potential but rare side effect of Velcade (bortezomib). It is important to disclose any existing liver problems before starting treatment and to be vigilant for any symptoms indicative of liver damage. Regular medical monitoring and prompt reporting of symptoms are essential to ensure timely intervention and management of this adverse effect.

Skin rash

Velcade (bortezomib) is a prescription drug used to treat multiple myeloma and mantle cell lymphoma. It is administered via injection by a healthcare provider.

In rare cases, Velcade can cause severe skin reactions. If you experience any symptoms of severe skin reactions, you should contact your doctor right away.

Some other side effects that have been reported with Velcade include:

• Peripheral neuropathy: This refers to nerve damage that typically affects the arms, hands, legs, or feet, causing pain, numbness, or weakness.
• Injection site reactions: These can include redness, swelling, and pain in the area where the drug was injected.
• Diarrhea: This can lead to weight loss, dehydration, and electrolyte imbalances if severe.
• Low blood pressure: Dehydration can further increase the risk of low blood pressure.
• Heart problems: These can include cardiac amyloidosis, heart failure, and heart rhythm problems.
• Lung problems: There have been reports of lung disorders, including interstitial lung disease and pneumonitis, in people receiving Velcade.

Frequently asked questions